Analyst: This Penny Stock Could Triple

PSTI stock hasn't touched $4.50 since 2014

Jul 31, 2018 at 2:15 PM
facebook X logo linkedin


B. Riley/FBR initiated coverage on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a "buy" rating and $4.50 price target -- a roughly 266% premium to last night's close. The analyst in coverage cited optimism surrounding the company's cell therapy treatments.

The bullish note has failed to spark a meaningful move higher in PSTI stock, though, which was last seen up 1% at $1.24. Longer term, the penny stock has been in a channel of lower highs and lows since topping out at an annual high of $2.12 last October -- though the $1.20 region has consistently emerged as a floor. What's more, the shares haven't traded near $4.50 since 2014.

psti stock daily chart july 31

Nevertheless, Pluristem Therapeutics has been a darling of analysts, with all four in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target stands all the way up at $4. This puts the lagging stock at risk of downgrades and price-target cuts on continued weakness.

 

*SPONSORED CONTENT*

How to collect 1 dividend check every day for LIFE

Did you know you could collect 1 dividend check every day the market is open? You could also do it starting with just $605! For me, I'm collecting 70 dividend checks every quarter…which averages around 1.1 dividend checks every business day. There's no trading behind this... no penny stocks or high-risk investments. All you do is buy and hold and you're set. There's no set up required either. If you start buying the dividend stocks I show you today... you could collect 1 dividend per day starting as early as this week. Click here for all the details.

*SPONSORED CONTENT*